Efficacy and Safety of Xacrel ® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Conditions:   Multiple Sclerosis;   Relapsing-Remitting Interventions:   Biological: Ocrelizumab (CinnaGen, Iran);   Biological: Ocrelizumab (Roche, Switzerland) Sponsor:   Cinnagen Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials